<DOC>
	<DOC>NCT00523380</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy. Patients will be treated for 6 months.</brief_summary>
	<brief_title>Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Advanced epithelial Ovarian Cancer (stage IIBIV) Persistent or progressive disease after or relapse within one year of completion of first line therapy Measurable or assessable disease Eastern Cooperative Oncology Group status less than or equal to 2 History of any other active malignancy Signs of CNS metastasis More than one prior chemotherapy regimen Radiotherapy (bone) less than 4 weeks prior to start of treatment and radiotherapy (visceral) less than 8 weeks First line chemotherapy completed at least 1 month prior to start of treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>